within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P01B_Antimalarials.P01BA02_Hydroxychloroquine;

model Hydroxychloroquine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.74,
    Cl = 3.111111111111111e-06,
    adminDuration = 600,
    adminMass = 200 / 1000000,
    adminCount = 1,
    Vd = 0.0442,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0025166666666666666,
    Tlag = 19.8,
    Vdp = 0.521,
    k12 = 1.6527777777777777e-05,
    k21 = 1.6527777777777777e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Hydroxychloroquine</td></tr><tr><td>ATC code:</td><td>P01BA02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>200</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>44.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.16</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Hydroxychloroquine is an antimalarial and immunomodulatory drug that is approved for treatment of malaria, rheumatoid arthritis, and systemic lupus erythematosus. It has also been investigated for off-label uses including COVID-19, though it is not approved for this indication.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in healthy adults following oral administration.</p><h4>References</h4><ol><li><p>Morita, S, et al., &amp; Yokota, N (2016). Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus. <i>Therapeutic drug monitoring</i> 38(2) 259–267. DOI:<a href=\"https://doi.org/10.1097/FTD.0000000000000261\">10.1097/FTD.0000000000000261</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26587870/\">https://pubmed.ncbi.nlm.nih.gov/26587870</a></p></li><li><p>Balevic, SJ, et al., &amp; Cohen-Wolkowiez, M (2019). Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. <i>Clinical pharmacokinetics</i> 58(4) 525–533. DOI:<a href=\"https://doi.org/10.1007/s40262-018-0712-z\">10.1007/s40262-018-0712-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30255310/\">https://pubmed.ncbi.nlm.nih.gov/30255310</a></p></li><li><p>Shimizu, M, et al., &amp; Yokogawa, N (2023). Pharmacokinetics of hydroxychloroquine in Japanese systemic lupus erythematosus patients with renal impairment. <i>Modern rheumatology</i> 33(5) 953–960. DOI:<a href=\"https://doi.org/10.1093/mr/roac113\">10.1093/mr/roac113</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36112484/\">https://pubmed.ncbi.nlm.nih.gov/36112484</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P01BA02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Hydroxychloroquine;
